Spyre Therapeutics Inc. (SYRE) — Cash Flow-to-Debt Ratio
Spyre Therapeutics Inc. (SYRE) has a Cash Flow-to-Debt Ratio of -0.62x as of March 2026, meaning its operating cash flow of $-57.54 Million could theoretically repay -1% of its total liabilities ($93.14 Million) in one year. Check Spyre Therapeutics Inc. (SYRE) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Spyre Therapeutics Inc. Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Spyre Therapeutics Inc. across 12 annual periods. Also explore SYRE asset base for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Spyre Therapeutics Inc. (2014–2025)
Year-by-year debt coverage analysis for Spyre Therapeutics Inc.. For market capitalisation and broader financial context, see Spyre Therapeutics Inc. market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.71x | $-169.25 Million | $62.55 Million | ▼ -55.9% |
| 2024 | -1.74x | $-157.41 Million | $90.68 Million | ▼ -174.2% |
| 2023 | -0.63x | $-99.91 Million | $157.84 Million | ▲ +83.5% |
| 2022 | -3.85x | $-80.14 Million | $20.84 Million | ▼ -86.0% |
| 2021 | -2.07x | $-53.72 Million | $25.98 Million | ▲ +40.6% |
| 2020 | -3.48x | $-75.78 Million | $21.79 Million | ▼ -22.3% |
| 2019 | -2.84x | $-65.69 Million | $23.10 Million | ▲ +8.9% |
| 2018 | -3.12x | $-32.19 Million | $10.31 Million | ▲ +27.2% |
| 2017 | -4.29x | $-24.61 Million | $5.74 Million | ▲ +6.7% |
| 2016 | -4.60x | $-18.84 Million | $4.10 Million | ▼ -6.8% |
| 2015 | -4.31x | $-10.98 Million | $2.55 Million | ▲ +37.9% |
| 2014 | -6.93x | $-7.33 Million | $1.06 Million | — |